Halozyme Therapeutics, Inc. has announced a new global collaboration and licensing agreement with Vertex Pharmaceuticals Incorporated aimed at advancing innovative drug delivery solutions for serious diseases. The agreement, signed through Halozyme’s wholly owned subsidiary Halozyme Hypercon, Inc., centers on the use of the company’s proprietary Hypercon™ technology.
Under the terms of the deal, Vertex will gain exclusive global rights to apply Hypercon™ technology across up to three drug targets. This platform is designed to enable the hyperconcentration of biologics and other therapies into smaller injection volumes, making treatments more convenient for patients by supporting at-home administration.
Hypercon™ represents a significant advancement in drug delivery, particularly for biologics that often require large injection volumes. By reducing the amount of liquid needed to deliver the same therapeutic dose, the technology has the potential to improve patient comfort, adherence, and accessibility. This is especially relevant for individuals managing chronic or serious conditions who may benefit from less frequent or more convenient dosing methods.
As part of the agreement, Vertex will make an upfront payment of $15 million to Halozyme, with the possibility of additional milestone payments tied to development and commercialization progress. Halozyme is also eligible to receive royalties on net sales of any products developed using the Hypercon™ platform.
Halozyme’s President and CEO, Helen Torley, highlighted the strategic importance of the collaboration, emphasizing that the agreement demonstrates the broad applicability of Hypercon™ technology. She noted that partnering with a company like Vertex, known for its innovation in developing transformative therapies, could help expand patient access to advanced biologics.
Vertex’s Chief Scientific Officer, Mark Bunnage, also underscored the value of integrating Hypercon™ into the company’s development capabilities. He indicated that the technology would enhance Vertex’s ability to design and deliver next-generation therapies more efficiently across multiple programs.
The partnership reflects a growing industry focus on improving not just the efficacy of treatments but also how they are administered. By combining Halozyme’s drug delivery innovation with Vertex’s therapeutic expertise, the collaboration aims to accelerate the development of more patient-friendly treatment options for a range of serious diseases.